In a report released today, Jessica Tassan from Piper Sandler reiterated a Buy rating on Health Catalyst (HCAT – Research Report), with a price target of $17.00. The company’s shares closed yesterday at $10.64.
According to TipRanks, Tassan is a 4-star analyst with an average return of 6.9% and a 55.43% success rate. Tassan covers the Healthcare sector, focusing on stocks such as Health Catalyst, Evolent Health, and Omnicell.
Health Catalyst has an analyst consensus of Strong Buy, with a price target consensus of $12.33, a 15.88% upside from current levels. In a report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $14.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Health Catalyst’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $73.77 million and a GAAP net loss of $22.03 million. In comparison, last year the company earned a revenue of $68.35 million and had a GAAP net loss of $45.74 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Health Catalyst (HCAT) Company Description:
Health Catalyst, Inc. engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology, and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers. The company was founded by Steven C. Barlow and Thomas D. Burton in 2008 and is headquartered in Salt Lake City, UT.
Read More on HCAT:
- ‘Profitability Is the Key’: Barclays Says These 3 Health Tech Stocks Are Poised for Growth
- Health Catalyst upgraded to Outperform at Evercore ISI on IT demand inflection
- Barclays starts healthcare technology, distribution with Neutral view
- Health Catalyst upgraded to Outperform from In Line at Evercore ISI
- Health Catalyst initiated with an Overweight at Barclays
